Periodic Announcement on Vaccine Safety of AstraZeneca COVID-19

Periodic Announcement on Vaccine Safety of AstraZeneca COVID-19

WHO Global Advisory Committee on COVID-19 Vaccine Safety has shared a report of some recent cases of blood clots with low platelets just after the vaccination with the AstraZeneca COVID-19 vaccine couple of weeks ago.

These subcommittees on their most recent meeting on 7th April reviewed some latest information from the European Medicines Agency along with United Kingdom’s Medicines and other Health products Regulatory Agency and other supporting states declared that;

Based on the latest data and information, a causal relationship between the vaccine and blood clotting with low platelets is considered plausible, but it is still not confirmed. Excellent research will be needed to understand the potential of relationships between vaccination and their possible risk factors.

The subcommittee of GAVS will continue to review and gather further data, the way they are doing since the beginning of the COVID vaccine program.

It is important to note that whilst concerning, the events under assessment are very rare, about 200 million individuals around the world are reported who received the AstraZeneca COVID-19 vaccines.

These rare and adverse effects of the vaccines should be checked against the risk of deaths from COVID-19 disease and the potential of the vaccines to prevent infections and reduce deaths because of diseases. At this point, at least 2.86 million people have died of COVID-19 disease across the world.

The majority of these rare Side effects within two- or three days after receiving the vaccination were mild and pretty common in nature. However, many individuals who experience severe symptoms – such as shortness of breath, swelling, persistent chest and abdominal pain, neurological symptoms, headaches or blurred vision, tiny blood spots under the skin beyond the site of the injection - from around four to 20 days following vaccination, need to have urgent medical attention. All healthcare service providers should know these case definitions and should provide clinical direction for patients introducing apoplexy and thrombocytopenia following Coronavirus vaccination. The GACVS subcommittee additionally recommended that a board of trustees of clinical specialists including hematologists and different experts should have a meeting for guidance on clinical analysis and explain the executives.

Dynamic observation, including sentinel site/clinic case-based examinations, should be considered to additionally portray these uncommon occasions. WHO has created format conventions that nations could adjust for such useful investigations. The GACVS will have a meeting again one week from now to audit extra information with further suggestions as applicable

WHO is monitoring the rollout of all COVID-19 vaccines very carefully and will work closely with countries to manage any potential risks with the use of science and data to drive response and recommendations.

In these fast-paced vaccination campaigns, it is pretty normal for countries to identify any potential adverse events that may occur just after the Vaccination and in any situation It does not mean that the events are linked to the vaccination itself, but it will be investigated to ensure every safety concerns that are raised after vaccination. Like all medicines, vaccines can also have side effects.

Microsure Works With Trusted Brands

Company Details

Iprotect Health Services and Solutions Ltd iprotect.bemicrosure.com Company No.: 691023 VAT No.: 3750836UH

Registered Address

The View Hunters Run Mulhuddart Dublin 15 Co. Dublin
Designed & Co-Developed By
Medcare & PPE
Partnership With
Airpure Tec MicroSURE Iprotect
Payment Method
World Pay Paypal